A Look At Tarsus Pharmaceuticals (TARS) Valuation After Adding Former Allergan CEO David Pyott To Its Board

Simply Wall St

Thu, February 19, 2026 at 10:15 AM GMT+9 2 min read

In this article:

TARS

+0.78%

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Tarsus Pharmaceuticals (TARS) shares are back in focus after the company added former Allergan CEO David E. I. Pyott to its Board of Directors, with Pyott also taking key committee roles.

See our latest analysis for Tarsus Pharmaceuticals.

The board appointment comes after a weaker period for the stock, with a 30 day share price return of an 11.1% decline and a year to date share price return of a 21.7% decline, even as the 3 year total shareholder return is around 4x.

If this kind of leadership change has you thinking about where else growth stories might emerge in healthcare, it could be worth scanning our list of 25 healthcare AI stocks as a starting point for ideas beyond Tarsus.

So with Tarsus shares down over the past month and year to date, yet priced below the average analyst target and carrying a solid value score, is this a genuine entry point or is the market already assuming future growth?

Most Popular Narrative: 27.7% Undervalued

At a last close of $63.27 against a widely followed fair value of about $87.50, the current price sits well below what the narrative suggests, putting extra attention on the long term growth and margin assumptions behind that gap.

The analysts have a consensus price target of $76.0 for Tarsus Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $92.0, and the most bearish reporting a price target of just $45.0.

Read the complete narrative.

Want to see what is baked into that higher fair value? The narrative leans on rapid revenue expansion, rising margins, and a future earnings profile that assumes meaningful scale. Curious which specific growth and profitability paths need to line up for that price to make sense over time?

Result: Fair Value of $87.50 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends heavily on XDEMVY continuing to gain traction, and on high SG&A and reimbursement pressures not capping the margins analysts are currently assuming.

Find out about the key risks to this Tarsus Pharmaceuticals narrative.

Next Steps

If the tone of this story feels optimistic but uncertain, it could be a good moment to look at the numbers yourself and move quickly to form your own view. You can start with our breakdown of 3 key rewards.

Story continues  

Ready for more investment ideas?

Before you move on, give yourself a broader watchlist by checking a few focused screeners that surface different kinds of opportunities you might otherwise miss.

Target potential mispricings by scanning our 53 high quality undervalued stocks that combine attractive pricing with solid fundamentals.

Prioritize resilience by reviewing 80 resilient stocks with low risk scores that score well on balance sheet strength and risk metrics.

Spot early standouts by browsing our screener containing 24 high quality undiscovered gems that have quality characteristics but sit outside the usual headlines.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include TARS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info